Table 1.

Effects of various suPAR types on podocyte integrin activation and kidney filter function

suPAR TypeSourceAccessionRecipientRouteDose (μg)TimeGlomerular β3 Integrin ActivityKidney PhenotypeReference
Full length, isoform 1, mouseDrosophila S2 cellsNM_01111B6 or 129 miceIntravenousUp to 10024 hNot studiedNo proteinuria, no podocyte FP effacement2
Full length, isoform 1, Fc chimera, mouseMouse NS0 cellsQ545X5B6 or 129 miceIntravenousUp to 10024 hNot studiedNo proteinuria, no podocyte FP effacement2
Full length, isoform 1, mouseDrosophila S2 cellsNM_01111B6 miceOsmotic pump2001 wkNot studiedNo proteinuria, no FP effacement2
Full length, isoform 1, Fc chimera mouseMouse NS0 cellsQ545X5uPAR KO mice 129/B6Intravenous2024 hIncreasedProteinuria1
EndogenousLPS inducedB6 miceEndogenousN/A24 hIncreasedSerum and urinary suPAR increased, proteinuria, podocyte FP effacement1
EndogenousLPS induceduPAR null kidney engrafted into B6 miceHost suPAR circulating into the engrafted uPAR null kidneyN/A24 hIncreasedsuPAR deposits into uPAR null kidney, podocyte FP effacement1
Secreted, isoform 2Plasmid DNABC010309B6 miceIntradermal electroporation80 DNA weekly1 moIncreasedFSGS-like changes, proteinuria1, 11
  • S2, Schneider 2; KO, knockout; FP, foot process.